Literature DB >> 21492999

Ascorbate and endocytosed Motexafin gadolinium induce lysosomal rupture.

Carsten Berndt1, Tino Kurz, Sarah Bannenberg, Ralf Jacob, Arne Holmgren, Ulf T Brunk.   

Abstract

Motexafin gadolinium (MGd) sensitizes malignant cells to ionizing radiation, although the underlying mechanisms for uptake and sensitization are both unclear. Here we show that MGd is endocytosed by the clathrin-dependent pathway with ensuing lysosomal membrane permeabilization, most likely via formation of reactive oxygen species involving redox-active metabolites, such as ascorbate. We propose that subsequent apoptosis is a synergistic effect of irradiation and high MGd concentrations in malignant cells due to their pronounced endocytic activity. The results provide novel insights into the mode of action of this promising anti-cancer drug, which is currently under clinical trials.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21492999     DOI: 10.1016/j.canlet.2011.03.023

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  4 in total

Review 1.  Ascorbic acid: chemistry, biology and the treatment of cancer.

Authors:  Juan Du; Joseph J Cullen; Garry R Buettner
Journal:  Biochim Biophys Acta       Date:  2012-06-20

2.  Lanthanides: Applications in Cancer Diagnosis and Therapy.

Authors:  Ruijie D Teo; John Termini; Harry B Gray
Journal:  J Med Chem       Date:  2016-02-19       Impact factor: 7.446

Review 3.  Clinically Evaluated Cancer Drugs Inhibiting Redox Signaling.

Authors:  D Lynn Kirkpatrick; Garth Powis
Journal:  Antioxid Redox Signal       Date:  2016-04-22       Impact factor: 8.401

4.  Monte Carlo study of radiation dose enhancement by gadolinium in megavoltage and high dose rate radiotherapy.

Authors:  Daniel G Zhang; Vladimir Feygelman; Eduardo G Moros; Kujtim Latifi; Geoffrey G Zhang
Journal:  PLoS One       Date:  2014-10-02       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.